RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$8.03
+0.15 (+1.90%)
Financial Highlights (FY 2026)
Revenue
218.29M
Net Income
-248,314,540
Gross Margin
88.1%
Profit Margin
-113.8%
Rev Growth
+14.8%
D/E Ratio
1.82
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.1% | 88.1% | 65.6% | 65.6% |
| Operating Margin | -94.6% | -85.1% | 22.7% | 23.0% |
| Profit Margin | -113.8% | -108.1% | 16.1% | 20.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 218.29M | 190.18M | 81.92M | 77.44M |
| Gross Profit | 192.29M | 167.53M | 53.74M | 50.80M |
| Operating Income | -206,461,774 | -161,888,479 | 18.58M | 17.83M |
| Net Income | -248,314,540 | -194,705,598 | 13.19M | 16.19M |
| Gross Margin | 88.1% | 88.1% | 65.6% | 65.6% |
| Operating Margin | -94.6% | -85.1% | 22.7% | 23.0% |
| Profit Margin | -113.8% | -108.1% | 16.1% | 20.9% |
| Rev Growth | +14.8% | +14.8% | +8.8% | +5.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 175.01M | 175.01M | 100.32M | 116.10M |
| Total Equity | 96.14M | 96.14M | 233.09M | 229.51M |
| D/E Ratio | 1.82 | 1.82 | 0.43 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -186,462,138 | -154,329,178 | 28.49M | 26.62M |
| Free Cash Flow | — | — | 20.59M | 19.17M |